AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16368830
Drug: Epidural neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural neostigmine infusion (500 microg bolus at end of surgery)
Trial: 16368830
Drug: Epidural neostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural neostigmine infusion (500 microg bolus before anesthesia induction)
Trial: 14561539
Drug: Implanon (etonogestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implanon (etonogestrel 68 mg, single‐rod)
Trial: 14561539
Drug: Norplant (levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norplant (levonorgestrel 36 mg, six capsules)
Trial: 2310661
Drug: Intravenous nisoldipine
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nisoldipine
Trial: 380737
Drug: Povidone-iodine spray
RxNorm normalized name: povidone-iodine Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone-iodine spray
Trial: 31418516
Drug: Add-on insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on insulin therapy
Trial: 29078817
Drug: High-dose pitavastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pitavastatin (4 mg)
Trial: 25377166
Drug: Oral route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral route (trainees)
Trial: 25377166
Drug: Oral route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral route (experts)
Trial: 17257177
Drug: Gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1200 mg (Group II, n = 25)
Trial: 17257177
Drug: Gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1200 mg and 20 mg/kg paracetamol (Group III, n = 25)
Trial: 17257177
Drug: Gabapentin (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (Group II) and Gabapentin + Paracetamol (Group III)
Trial: 17257177
Drug: Gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1200 mg (Group II) and Gabapentin + Paracetamol (Group III)
Trial: 11961238
Drug: G-CSF (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (1 microg/kg IV)
Trial: 11961238
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 microg/kg IV)
Trial: 11961238
Drug: Dexamethasone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1 mg/kg twice daily)
Trial: 21040545
Drug: Directly-observed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly-observed therapy (DOT)
Trial: 9098476
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of cyproterone acetate and 20 mg of ethynyl‐estradiol in an inversal sequential scheme for six months
Trial: 2478788
Drug: UD‐CG 115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UD‐CG 115 BS 5 mg p.o.
Trial: 2478788
Drug: UD‐CG 115
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UD‐CG 115 BS 10 mg p.o.
Trial: 2478788
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with 10 mg of UD‐CG 115 BS/day over 5 days
Trial: 2478788
Drug: Dobutamine (optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine (optimal dose)
Trial: 6993122
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment followed by delayed operation (n=30)
Trial: 31680331
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g fibrinogen concentrate
Trial: 28228426
Drug: Probiotic (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) 2 capsules/d, 1.5 billion colony-forming units/capsule for 8 weeks
Trial: 22464209
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of embryo culture supernatant before embryo transfer
Trial: 19924786
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment of both primary tumor and metastases
Trial: 19924786
Drug: Any local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any local treatment of either primary tumor or metastases
Trial: 19924786
Drug: Absence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Absence of local treatment
Trial: 12184365
Drug: Subcutaneous (s.q.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.q.) administration of AVA
Trial: 8534466
Drug: 70% N2O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70% N2O in 30% O2 administered by face mask for 120 seconds
Trial: 8534466
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g of EMLA cream under an occlusive dressing for a minimum of 60 minutes
Trial: 2178535
Drug: Ranitidine, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 300 mg orally, administered 1 hour before running
Trial: 2178535
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered after a low-fat breakfast before baseline pH recording
Trial: 17533210
Drug: Complex clinical
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex clinical models (including 2-hour post-OGTT glucose, fasting insulin, C-reactive protein, Gutt insulin sensitivity index, homeostasis model insulin resistance)
Trial: 15570070
Drug: Marimastat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marimastat (10 mg bid)
Trial: 15570070
Drug: Marimastat (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marimastat (10 mg bid) with plasma concentration ≥ 10 ng/mL
Trial: 9458569
Drug: Oral presentation
RxNorm normalized name: Gas-X Prevention Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral presentation about infant immunization
Trial: 8169430
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses after two injections
Trial: 28438182
Drug: Forced fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forced fluid removal with a therapeutic target of negative net fluid balance ≥1 mL/kg/h
Trial: 22560371
Drug: D-cycloserine (50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (50mg once weekly)
Trial: 17701037
Drug: Gemcitabine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 400 mg/m2 (dose level 0)
Trial: 17701037
Drug: Gemcitabine 200
RxNorm normalized name: gemcitabine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 200 mg/m2 (dose level -1)
Trial: 17701037
Drug: Hematologic toxicity
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hematologic toxicity at dose level 0
Trial: 12613268
Drug: Esberitox N
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esberitox N (herbal immunomodulator), dosage: 3 x 2 tablets daily, duration: from 3 days prior to injection to 2 weeks after injection
Trial: 12613268
Drug: Placebo, dosage:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, dosage: 3 x 2 tablets daily, duration: from 3 days prior to injection to 2 weeks after injection
Trial: 11910665
Drug: CEE therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE therapy (0.625 mg/day of conjugated equine estrogen)
Trial: 11910665
Drug: CEE/MPA therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE/MPA therapy (0.625 mg/day of CEE and 2.5 mg/day of medroxyprogesterone acetate)
Trial: 8730943
Drug: Antidepressants and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants and behavioural counselling
Trial: 1924235
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of 10% isoniazid solution
Trial: 1924235
Drug: Oral isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isoniazid
Trial: 22294737
Drug: n-3 LCPUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 LCPUFA supplementation (fish oil capsules providing 900 mg of n-3 LCPUFA daily)
Trial: 22294737
Drug: Control (matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (matched vegetable oil capsules without n-3 LCPUFA)
Trial: 18802718
Drug: Buffered isotonic
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered isotonic saline solution
Trial: 16551896
Drug: 5-day opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day opioid weaning using oral methadone
Trial: 16551896
Drug: 10-day opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day opioid weaning using oral methadone
Trial: 12923131
Drug: Methotrexate and
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and Mifepristone (600 mg given orally)
Trial: 12923131
Drug: Methotrexate and
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and Mifepristone (600 mg given orally) with progesterone level >/=10 ng/l
Trial: 12923131
Drug: Methotrexate and
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and Placebo with progesterone level >/=10 ng/l
Trial: 8775573
Drug: Pre-exercise glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-exercise glycerol hydration (1.2 gm/kg glycerol in 26 ml/kg solution)
Trial: 8775573
Drug: Pre-exercise placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-exercise placebo hydration (26 ml/kg of aspartame flavored water)
Trial: 25005331
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein pre-load (50 g whey in 250 ml water)
Trial: 25005331
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 ml water)
Trial: 22887019
Drug: HQK-1001 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HQK-1001 at 10 or 20 mg/kg doses
Trial: 22887019
Drug: HQK-1001 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HQK-1001 at 30 mg/kg/day
Trial: 16133954
Drug: Loperamide 2
RxNorm normalized name: loperamide 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 2 mg/day
Trial: 16133954
Drug: Loperamide 4
RxNorm normalized name: loperamide 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 4 mg/day
Trial: 16133954
Drug: Loperamide 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 6 mg/day
Trial: 11896377
Drug: Light exercise
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light exercise therapy
Trial: 10396858
Drug: I-131 therapy
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-131 therapy
Trial: 10396858
Drug: I-131 therapy
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-131 therapy + external beam radiotherapy (RT)
Trial: 1974505
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg once daily for 4 weeks
Trial: 1974505
Drug: Carvedilol 25
RxNorm normalized name: carvedilol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 25 mg once daily + HCTZ 25 mg once daily for 10 weeks
Trial: 1974505
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg once daily + HCTZ 25 mg once daily for 10 weeks
Trial: 6116461
Drug: Alfentanil (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (0.5 mg/ml)
Trial: 6116461
Drug: Fentanyl (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.05 mg/ml)
Trial: 31097414
Drug: Stepped-care intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care intervention (eight sessions of individual problem-solving therapy, with an extra two to four sessions if needed) plus enhanced usual care
Trial: 17101741
Drug: NXY-059 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXY-059 (15 mg/mL) during 12 hours
Trial: 12800796
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy and radiation
Trial: 12800796
Drug: Intraperitoneal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal treatment
Trial: 11155057
Drug: Remifentanil hydrochloride,
RxNorm normalized name: Remifentanil Hydrochloride, 1 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil hydrochloride, bolus doses of 1 microgram/kg followed by continuous infusions of 0.1‐0.5 microgram/kg/min, titrated to effect.
Trial: 9124202
Drug: G‐CSF (arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (arm A)
Trial: 9124202
Drug: G‐CSF followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF followed by GM‐CSF (arm B)
Trial: 29095347
Drug: Reference oral
RxNorm normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Reference oral liquid formula (Neocate) (group 2)
Trial: 26373657
Drug: Longitudinal care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longitudinal care (telephone-based counseling and nicotine replacement therapy for 12 months)
Trial: 26373657
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (standard 8-week treatment)
Trial: 22464164
Drug: HES 130/0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES 130/0.4 preload (500 mL)
Trial: 22464164
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution preload (1000 mL)
Trial: 16117771
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) instilled locally before implant placement
Trial: 12324668
Drug: Daily rhDNase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily rhDNase (2.5 mg once daily)
Trial: 12324668
Drug: Alternate day
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate day rhDNase (2.5 mg every other day)
Trial: 12324668
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (5 ml 7% HS twice daily)
Trial: 12080402
Drug: Walnut diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut diet (12.5% of energy from walnuts, 44-58 g/day)
Trial: 9733272
Drug: Cyclophosphamide (CP)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CP) at a dose of 50 mg/kg daily infused intravenously over 1 hour for 4 days (in aplastic anemia patients)
Trial: 9733272
Drug: Cyclophosphamide (CP)
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (CP) at a dose of 60 mg/kg by i.v. infusion over 1 hour daily for 2 days followed by total body irradiation (in leukemia patients)
Trial: 8296403
Drug: Intermittent suction
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent suction and pressure (Vacusac treatment)
Trial: 28202500
Drug: Walking intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Walking intervention comprising Macmillan's 'Move More' information, a short motivational interview recommending to walk for at least 30 minutes on alternate days and attend a volunteer-led group walk weekly.
Trial: 18675597
Drug: Endometrial aspiration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial aspiration before saline infusion sonography (SIS)
Trial: 18675597
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion sonography (SIS) before endometrial aspiration
Trial: 12867217
Drug: Aprepitant 375
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 375 mg PO, dexamethasone 20 mg PO, ondansetron 32 mg IV on day 1, followed by aprepitant 250 mg PO and dexamethasone 8 mg PO on days 2 through 5
Trial: 12867217
Drug: Aprepitant 125
RxNorm normalized name: aprepitant 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125 mg PO with granisetron 2 mg PO on day 1, followed by aprepitant 80 mg PO on days 2 and 3
Trial: 12867217
Drug: Dexamethasone 20
RxNorm normalized name: dexamethasone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 20 mg PO and ondansetron 32 mg IV on day 1, followed by dexamethasone 8 mg PO on days 2 through 5
Trial: 12867217
Drug: Granisetron 2
RxNorm normalized name: granisetron 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron 2 mg PO on day 1 only
Trial: 9194649
Drug: 2, 4
RxNorm normalized name: Kera-42, 42% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2, 4 or 8 mg of micronized MENT (single i.m. injections)
Trial: 9194649
Drug: 1, 2
RxNorm normalized name: 1, 2-benzenediol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2 or 4 mg of MENT (six consecutive daily i.m. injections)
Trial: 1587077
Drug: Targeted intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted intermittent medication
Trial: 1587077
Drug: Upward dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upward dose adjustment
Trial: 11694805
Drug: Oral zafirlukast
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral zafirlukast (40 mg)
Trial: 11694805
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of inhaled salmeterol and oral zafirlukast
Trial: 8194818
Drug: DMSO gel
RxNorm normalized name: DMSO
DrugBank: Dimethyl sulfoxide (DB01093)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DMSO gel 10% applied three times a day (n = 77)
Trial: 8194818
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel excipient (n = 80)
Trial: 31858950
Drug: Active control
RxNorm normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active control condition of daily maths activities
Trial: 27400966
Drug: Nondirective coaching
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nondirective coaching for subgroups (income above median, recent quit attempts, alternative therapies)
Trial: 24522623
Drug: Lottery incentive
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [BEACH DREAM GLITTERY SUNSCREEN SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lottery incentive with expected daily value of $1.40 (n=21)
Trial: 24522623
Drug: Lottery incentive
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [BEACH DREAM GLITTERY SUNSCREEN SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lottery incentive with expected daily value of $2.80 (n=26)
Trial: 20068289
Drug: Vinegar (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinegar (10 g) during mealtime
Trial: 20068289
Drug: Vinegar (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinegar (10 g) 5 hours before meal
Trial: 19008149
Drug: BNP guided
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP guided therapy
Trial: 16079784
Drug: Estimates of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estimates of k(loss) and EDV(2) using a novel application of a multilinear solution for the two-tissue compartment FDOPA model.
Trial: 10423659
Drug: Lisinopril (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (n = 193)
Trial: 6844367
Drug: Phentermine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentermine (30 mg capsule daily)
Trial: 6844367
Drug: Diethylpropion (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylpropion (75 mg tablet daily)
Trial: 25895909
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with standardized JC pollen extract (CEDARTOLEN®) at a maintenance dose of 2,000 Japanese allergy units (JAU)
Trial: 25895909
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with standardized JC pollen extract (CEDARTOLEN®)